Revium Rx 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OID
RVRC
Revium RxRevium Rx, a preclinical biopharmaceutical company, reported a significant net loss of $13.4 million in 2025 and faces substantial doubt about its ability to continue as a going concern, compounded by a dispute over its Nano-Candesartan license.